Apr 5, 2022
Apnimed will participate in 1×1 investor meetings at the 21st Needham Healthcare Conference taking place virtually April 11-14, 2022.
Mar 10, 2022
Apnimed will participate in the 32nd Annual Oppenheimer Conference taking place March 15-17, 2022 virtually.
Mar 9, 2022
Data from Apnimed’s Phase 2 study APC-004 will be featured in the company’s oral presentation at World Sleep 2022 in Rome, Italy on Monday, March 14.
Feb 7, 2022
Apnimed company management will participate in 1×1 investor meetings at the SVB Leerink Global Healthcare Conference.
Jan 6, 2022
Larry Miller, M.D., Chief Executive Officer, will present in a virtual format on Wednesday, January 12th at 5:30 p.m. ET.
Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)
Dec 16, 2021
Apnimed announces the dosing of the first patient in the Phase 2b MARIPOSA study of AD109.
Apnimed Achieves Meaningful Results in Proof-of-Concept Crossover Study with Oral Therapeutic Candidates AD504 and AD182 for the Treatment of Obstructive Sleep Apnea
Nov 16, 2021
Apnimed announces positive results from a proof-of-concept crossover study in patients with OSA evaluating AD504 and AD182.
Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Treatment for the Disease
Oct 13, 2021
Apnimed today announced positive data across multiple endpoints from its Phase 2 randomized, double-blind, placebo-controlled, crossover clinical trial (Study APC-004) evaluating the efficacy and safety of AD109 as a treatment for patients with mild to moderate OSA.
Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment
Oct 13, 2021
Apnimed announced positive data across multiple endpoints from a Phase 2 randomized, double-blind, placebo-controlled, four-period, single-dose crossover factorial clinical trial (APC-003), and a 28-day open-label extension study, evaluating AD109 as a treatment in patients with mild to severe OSA.
Sep 27, 2021
Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that Rob Rode has joined the company as Chief Commercial Officer. Mr. Rode has more than 27 years of experience leading global sales and marketing efforts in the biopharmaceutical field and will be responsible for developing and executing Apnimed’s commercial strategy.